癌症免疫治疗通过阻止特定免疫检查点分子，如程序性细胞死亡1和细胞毒性T淋巴细胞抗原4，在各种恶性肿瘤中产生了令人鼓舞的结果。 然而，只有很少数患者对免疫检查点阻滞疗法做出反应，这是由于肿瘤细胞的免疫原性差和免疫抑制的肿瘤微环境。越来越多的证据表明，包括奥沙利铂和多柔比星在内的化疗药物不仅能够介导直接的肿瘤细胞细胞毒性，还可以诱导免疫原性癌细胞死亡，在肿瘤微环境中刺激强有力的抗癌免疫反应。在本综述中，我们总结了基于免疫检查点抑制剂加免疫原性细胞死亡诱导剂的癌症联合治疗的最新进展。尽管存在一些临床失败和挑战，但免疫原性细胞死亡诱导剂在临床前和临床试验中与免疫检查点抑制剂联合用于抗癌治疗中显示出巨大的潜力。版权所有©2023 Elsevier B.V.出版。

Cancer immunotherapies have yielded promising outcomes in various malignant tumors by blocking specific immune checkpoint molecules, such as programmed cell death 1 and cytotoxic T lymphocyte antigen 4. However, only a few patients respond to immune checkpoint blockade therapy because of the poor immunogenicity of tumor cells and immune-suppressive tumor microenvironment. Accumulating evidence suggests that chemotherapeutic agents, including oxaliplatin and doxorubicin, not only mediate direct cytotoxicity in tumor cells but also induce immunogenic cancer cell death to stimulate a powerful anti-cancer immune response in the tumor microenvironment. In this review, we summarize the recent advances in cancer combination therapy based on immune checkpoint inhibitors plus immunogenic cell death inducers. Despite some clinical failures and challenges, immunogenic cell death inducers have displayed great potential when combined with immune checkpoint inhibitors for anti-cancer treatment in both preclinical studies and clinical trials.Copyright © 2023. Published by Elsevier B.V.